[Form 4] Abbott Laboratories Insider Trading Activity

Rhea-AI Filing Summary

Philip P. Boudreau, EVP and CFO of Abbott Laboratories (ABT), filed a Form 4 reporting insider sales dated 08/08/2025. The filing lists a sale transaction reported at a weighted average price of $134.551 and notes transaction prices in the range $134.551 to $134.58. The table shows 5,550 shares sold (denoted D) and a direct beneficial ownership following the reported transaction of 51,003 shares. It also reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.

The Form 4 is signed on behalf of Mr. Boudreau by an attorney-in-fact and dated 08/11/2025. The filing includes an explicit offer to provide detailed per-price sale breakdowns upon request and discloses the reporting person’s title and relationship to the issuer. No additional financial metrics, forward-looking statements, or explanations of purpose for the sale are provided in the filing.

Positive

• Timely and detailed disclosure of the insider sale including weighted average price and price range
• Trust balance disclosed (361 shares), and an explicit offer to provide per-price sale breakdowns on request

Negative

• None.

Insights

Financial Analyst

TL;DR Routine officer stock sale disclosed; amounts and price range are specified, with remaining direct and trust balances shown.

The filing documents a transaction dated 08/08/2025 by Abbott EVP/CFO Philip P. Boudreau. It specifies a weighted average sale price reported at $134.551 with transaction prices ranging to $134.58, a sale quantity shown as 5,550 shares (D), resulting in direct beneficial ownership of 51,003 shares, and an indirect trust balance of 361 shares. For market impact assessment, the filing gives no context about percent ownership or company market capitalization, so valuation or relative-size conclusions cannot be drawn from the document alone.

Corporate Governance Expert

TL;DR Disclosure complies with Section 16 reporting: sale details, price range, and trust balance are transparently reported.

The Form 4 provides the required Section 16 disclosure for an insider transaction by an executive officer. It includes the transaction date, weighted average price, a stated range of execution prices, and an explicit note offering to supply per-price breakdowns. It also identifies the reporter's role (EVP and CFO) and the indirect holdings in a stock retirement trust. The form does not state any plan code or 10b5-1 designation, nor does it explain the reason for the sale; those absences are factual observations contained in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Philip P

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	08/08/2025		S		5,550	D	$134.551(1)	51,003	D
Common shares without par value								361(2)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.551 to $134.58, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.

	/s/ Philip P. Boudreau by Jessica H. Paik, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Philip P. Boudreau report on the Form 4 for ABT?

He reported a sale dated 08/08/2025 with a weighted average price of $134.551 and transaction prices ranging from $134.551 to $134.58.

How many shares were reported sold and how many does he beneficially own after the transaction?

The filing shows 5,550 shares sold (D) and a direct beneficial ownership after the transaction of 51,003 shares.

Does the Form 4 disclose any holdings in employee or retirement trusts for ABT?

Yes: the filing reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.

What is the reporting person’s role at Abbott Laboratories?

Philip P. Boudreau is listed as EVP and CFO of Abbott Laboratories on the Form 4.

When was the Form 4 signed and by whom?

The Form 4 is signed on behalf of Philip P. Boudreau by Jessica H. Paik, Attorney-in-Fact, dated 08/11/2025.

Does the filing explain why the shares were sold or reference a 10b5-1 plan?

No explicit explanation of the reason for the sale and no 10b5-1 plan designation are included in the provided filing text.